Press Releases
Spark Therapeutics, Pfizer Inc announce data from initial subjects in hemophilia B trial
Subjects received one-time administration of a highly optimized gene therapy at initial low dose without the need for immunosuppression Therapeutic Factor IX activity sustained at levels exceeding those considered sufficient to reduce the risk of joint bleeds and...
Press Releases
Novartis announces FortiHFy clinical programme of Entresto
Fortifying Heart Failure clinical evidence and patient quality of life (FortiHFy) is an umbrella clinical program comprising over 40 active or planned trials The global clinical program will generate additional data on symptom reduction, efficacy, safety, quality of...
Press Releases
AstraZeneca highlights continued progress of oncology pipeline at ASCO 2016
73 abstracts presented at ASCO with 19 related to Lynparza and new potential medicines targeting DNA damage response in multiple tumour typesContinued momentum of immuno-oncology medicines including new data on durvalumab in bladder cancer, underpinning the Breakthrough Therapy Designation,...
Press Releases
Amgen Inc Data To Be Presented At ASCO 2016 Demonstrates More Insights Into Treatment Options For Patients
New Analysis From Phase 3 Trial of Kyprolis® (Carfilzomib) Combination Treatment in Relapsed Multiple Myeloma Patients With Early Disease ProgressionPhase 1/3 MASTERKEY-265 Study Abstracts Present Data on IMLYGIC® (Talimogene Laherparepvec) in Combination With Pembrolizumab in Patients With Unresected Stage...
Press Releases
Merck and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting
14 avelumab abstracts at ASCO 2016 highlight significant progress being made by the collaboration between Merck KGaA, Darmstadt, Germany, and Pfizer Two oral presentations: avelumab investigated as a second-line treatment for metastatic Merkel cell carcinoma and in advanced...
Press Releases
Merck & Co Inc Final overall survival data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma To Be Presented at 2016 ASCO Annual Meeting
Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate Overall Survival Compared to Ipilimumab, Shows Continued Benefit with Longer Follow-Up. KEYNOTE-001 Findings Show Continued Benefit in Response...
Press Releases
GlaxoSmithKline presents new data from Breo Ellipta SUMMIT study in patients with COPD at ATS Conference
GlaxoSmithKline and Innoviva, Inc announced that GlaxoSmithKline plc (GSK) presented new data at the American Thoracic Society (ATS) Conference from two pre-specified analyses from the Study to Understand Mortality and MorbidITy (SUMMIT) trial. One demonstrated that...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read